ROBERTO MINA

Assistant professor

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Roberto Mina is an Assistant Professor at the University of Torino, affiliated with the Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. His research focuses primarily on multiple myeloma, with recent articles exploring topics such as the efficacy of daratumumab and carfilzomib-based therapies, as well as the implications of minimal residual disease monitoring. Additionally, he has contributed to the understanding of infection risks in multiple myeloma patients and the impact of COVID-19 on lymphoma diagnoses.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Francesca Gay

Associate Professor

University of Turin

ITALY

View details

Nicola Giuliani

Associate Professor

Università degli Studi di Pavia

ITALY

View details

Matteo Giovanni Della Porta

Head

Center for Accelerating Leukeima/Lymphoma Research (CALR)

ITALY

View details

Benjamin Derman

Assistant Professor

University of Chicago

UNITED STATES

View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Michele Cea

University of Genoa

ITALY

View details

Paolo de Fabritiis

University of Rome Tor Vergata

ITALY

View details

Lawrence Boise

Professor

Emory University

UNITED STATES

View details

david jaye

Associate Professor

Emory University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ROBERTO MINA

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma

Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS

Are we ready for an MRD-driven approach in multiple myeloma?

Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts

It’s in your (peripheral) blood

Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report

Minimal Residual Disease in Multiple Myeloma

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. <i>J. Clin. Med.</i> 2020, <i>9</i>, 2142

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives

Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Collaborators (9)

Francesca Gay

Nicola Giuliani

Matteo Giovanni Della Porta

Benjamin Derman

Saad Usmani

Michele Cea

Paolo de Fabritiis

Lawrence Boise

david jaye

Make your next move.